{"count": 5, "results": [{"_id": "35273494", "pmid": 35273494, "pmcid": "PMC8902464", "title": "Metformin Alleviates Endometriosis and Potentiates Endometrial Receptivity via Decreasing VEGF and MMP9 and Increasing Leukemia Inhibitor Factor and HOXA10", "journal": "Front Pharmacol", "authors": ["Cheng J", "Li C", "Ying Y", "Lv J", "Qu X", "McGowan E", "Lin Y", "Zhu X"], "date": "2022-02-22T00:00:00Z", "doi": "10.3389/fphar.2022.750208", "meta_date_publication": "2022", "meta_volume": "13", "meta_issue": "", "meta_pages": "750208", "score": 50269.836, "text_hl": "... Results: @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ treatment significantly suppressed the growth of @<m>DISEASE_Peri_Implantitis</m> @DISEASE_MESH:D057873 @@@endometriotic implants@@@. ", "citations": {"NLM": "Cheng J, Li C, Ying Y, Lv J, Qu X, McGowan E, Lin Y, Zhu X. Metformin Alleviates Endometriosis and Potentiates Endometrial Receptivity via Decreasing VEGF and MMP9 and Increasing Leukemia Inhibitor Factor and HOXA10 Front Pharmacol. 2022;13():750208. PMID: 35273494", "BibTeX": "@article{35273494, title={Metformin Alleviates Endometriosis and Potentiates Endometrial Receptivity via Decreasing VEGF and MMP9 and Increasing Leukemia Inhibitor Factor and HOXA10}, author={Cheng J and Li C and Ying Y and Lv J and Qu X and McGowan E and Lin Y and Zhu X}, journal={Front Pharmacol}, volume={13}, pages={750208}}"}}, {"_id": "35158846", "pmid": 35158846, "pmcid": "PMC8833654", "title": "Metformin as a Potential Treatment Option for Endometriosis", "journal": "Cancers (Basel)", "authors": ["Kimber-Trojnar Ż", "Dłuski DF", "Wierzchowska-Opoka M", "Ruszała M", "Leszczyńska-Gorzelak B"], "date": "2022-01-24T00:00:00Z", "doi": "10.3390/cancers14030577", "meta_date_publication": "2022 Jan 24", "meta_volume": "14", "meta_issue": "3", "meta_pages": "", "score": 50267.81, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ regresses @<m>DISEASE_Peri_Implantitis</m> @DISEASE_MESH:D057873 @@@endometriotic implants@@@ by increasing the activity of superoxide dismutase. ", "citations": {"NLM": "Kimber-Trojnar Ż, Dłuski DF, Wierzchowska-Opoka M, Ruszała M, Leszczyńska-Gorzelak B. Metformin as a Potential Treatment Option for Endometriosis Cancers (Basel). 2022 Jan 24;14(3):. PMID: 35158846", "BibTeX": "@article{35158846, title={Metformin as a Potential Treatment Option for Endometriosis}, author={Kimber-Trojnar Ż and Dłuski DF and Wierzchowska-Opoka M and Ruszała M and Leszczyńska-Gorzelak B}, journal={Cancers (Basel)}, volume={14}, number={3}}"}}, {"_id": "20133323", "pmid": 20133323, "title": "The effects of metformin and letrozole on endometriosis and comparison of the two treatment agents in a rat model.", "journal": "Hum Reprod", "authors": ["Oner G", "Ozcelik B", "Ozgun MT", "Serin IS", "Ozturk F", "Basbug M"], "date": "2010-04-01T00:00:00Z", "doi": "10.1093/humrep/deq016", "meta_date_publication": "2010 Apr", "meta_volume": "25", "meta_issue": "4", "meta_pages": "932-7", "score": 50059.52, "text_hl": "CONCLUSIONS: @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and @CHEMICAL_Letrozole @CHEMICAL_MESH:D000077289 @@@letrozole@@@ caused a statistically significant regression of @<m>DISEASE_Peri_Implantitis</m> @DISEASE_MESH:D057873 @@@endometriotic implants@@@. ", "citations": {"NLM": "Oner G, Ozcelik B, Ozgun MT, Serin IS, Ozturk F, Basbug M. The effects of metformin and letrozole on endometriosis and comparison of the two treatment agents in a rat model. Hum Reprod. 2010 Apr;25(4):932-7. PMID: 20133323", "BibTeX": "@article{20133323, title={The effects of metformin and letrozole on endometriosis and comparison of the two treatment agents in a rat model.}, author={Oner G and Ozcelik B and Ozgun MT and Serin IS and Ozturk F and Basbug M}, journal={Hum Reprod}, volume={25}, number={4}, pages={932-7}}"}}, {"_id": "20035912", "pmid": 20035912, "title": "Metformin regresses endometriotic implants in rats by improving implant levels of superoxide dismutase, vascular endothelial growth factor, tissue inhibitor of metalloproteinase-2, and matrix metalloproteinase-9.", "journal": "Am J Obstet Gynecol", "authors": ["Yilmaz B", "Sucak A", "Kilic S", "Aksakal O", "Aksoy Y", "Lortlar N", "Sut N", "Gungor T"], "date": "2010-04-01T00:00:00Z", "doi": "10.1016/j.ajog.2009.10.873", "meta_date_publication": "2010 Apr", "meta_volume": "202", "meta_issue": "4", "meta_pages": "368.e1-8", "score": 50053.69, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ regresses @<m>DISEASE_Peri_Implantitis</m> @DISEASE_MESH:D057873 @@@endometriotic implants@@@ in @SPECIES_10116 @@@rats@@@ by improving implant levels of superoxide dismutase, vascular endothelial growth factor, @GENE_TIMP2 @GENE_29543 @@@tissue inhibitor of metalloproteinase-2@@@, and @GENE_MMP9 @GENE_81687 @@@matrix metalloproteinase-9@@@.", "citations": {"NLM": "Yilmaz B, Sucak A, Kilic S, Aksakal O, Aksoy Y, Lortlar N, Sut N, Gungor T. Metformin regresses endometriotic implants in rats by improving implant levels of superoxide dismutase, vascular endothelial growth factor, tissue inhibitor of metalloproteinase-2, and matrix metalloproteinase-9. Am J Obstet Gynecol. 2010 Apr;202(4):368.e1-8. PMID: 20035912", "BibTeX": "@article{20035912, title={Metformin regresses endometriotic implants in rats by improving implant levels of superoxide dismutase, vascular endothelial growth factor, tissue inhibitor of metalloproteinase-2, and matrix metalloproteinase-9.}, author={Yilmaz B and Sucak A and Kilic S and Aksakal O and Aksoy Y and Lortlar N and Sut N and Gungor T}, journal={Am J Obstet Gynecol}, volume={202}, number={4}, pages={368.e1-8}}"}}, {"_id": "23305503", "pmid": 23305503, "title": "Comparison of antiproliferative effects of metformine and progesterone on estrogen-induced endometrial hyperplasia in rats.", "journal": "Gynecol Endocrinol", "authors": ["Tas M", "Kutuk MS", "Serin IS", "Ozgun MT", "Oner G", "Ozturk F"], "date": "2013-04-01T00:00:00Z", "doi": "10.3109/09513590.2012.743010", "meta_date_publication": "2013 Apr", "meta_volume": "29", "meta_issue": "4", "meta_pages": "311-4", "score": 50050.562, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ has been shown to inhibit the growth of @<m>DISEASE_Peri_Implantitis</m> @DISEASE_MESH:D057873 @@@endometriotic implants@@@, and reverse @DISEASE_Endometrial_Hyperplasia @DISEASE_MESH:D004714 @@@endometrial hyperplasia@@@ when combined with oral contraceptive in a case report. ", "citations": {"NLM": "Tas M, Kutuk MS, Serin IS, Ozgun MT, Oner G, Ozturk F. Comparison of antiproliferative effects of metformine and progesterone on estrogen-induced endometrial hyperplasia in rats. Gynecol Endocrinol. 2013 Apr;29(4):311-4. PMID: 23305503", "BibTeX": "@article{23305503, title={Comparison of antiproliferative effects of metformine and progesterone on estrogen-induced endometrial hyperplasia in rats.}, author={Tas M and Kutuk MS and Serin IS and Ozgun MT and Oner G and Ozturk F}, journal={Gynecol Endocrinol}, volume={29}, number={4}, pages={311-4}}"}}]}